AEON Biopharma, Inc.

AEONdata completeness 75%4 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'totalDebt'; no data for concept 'interestExpense'

i. The business — what you’d actually own

Figure	FY 2021	FY 2022	FY 2024	FY 2025
Revenue	—	—	—	—
Net income	$8.2M¹	−$52.6M²	$42M³	−$39.2M³
Operating cash flow	−$1.49M⁴	−$35.6M⁵	−$20.3M⁶	−$17.3M⁶
Capital expenditure	—	$306,000⁷	—	$4,000⁸
Free cash flow (derived)	—	−$35.9M⁵	—	−$17.3M⁶
Total debt	—	—	—	—
Cash & equivalents	$497,412⁹	$9.75M¹⁰	$13,000¹¹	$3.01M¹¹
Diluted shares	—	138.8M	575,945	9.9M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal

If you owned

Net assets behind them

−$55.46

your share of equity

Profit it earned you last year

−$39.53

Free cash flow it threw off

−$17.45

Debt you’d be carrying

—

10 shares is a claim on −$55.46 of net worth that earned you −$39.53 and generated −$17.45 of cash last year.

iii. Is this a good business?

Moat signal · return on equity

— avg · 4y

Not enough data in the filings for a return-on-capital reading.

Management signal · capital allocation

−93% shares · 4y

Share count is down 93% over 4 years — management has been buying back stock, quietly handing owners a bigger slice.

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0

DCF · Growth Exit 10Y

not applicable

only 2 years of FCF (need ≥3) — model not applicable

DCF · Growth Exit 5Y

not applicable

only 2 years of FCF (need ≥3) — model not applicable

Earnings Power Value

not applicable

normalized (5y-median) earnings non-positive — EPV undefined

Graham Number

not applicable

diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts